Trastuzumab deruxtecan, a HER2-targeted antibody–drug conjugate (ADC) used in the treatment of HER2-positive breast cancer, has been associated with ILD, with an incidence of 14% reported in clinical studies [22]. This evidence concerns the gene ERBB2 and breast cancer.